阿里健康(00241.HK)開通「阿茲夫定保供」專區 優先為農村用戶提供新冠藥品
阿里健康(00241.HK)公布,昨日(25日)在國家農業農村部、工信部、商務部和國家衛健委等四部委的指導下,阿里健康義診服務開通「阿茲夫定保供」專區,優先為農村地區的用戶提供阿茲夫定等新冠藥品,用戶只需打開淘寶App搜索「阿茲夫定保供」就能直達服務頁面,每日問診時段為早上10時至晚上9時。
公司指出,來自農村地區的用戶買到所需藥品需要四步,首先在線填寫預診單,然後與醫生詳細溝通病情,經醫生酌情開具處方後,就可在線支付購藥,等待藥品配送到家。
此外,阿里健康指近期一直在政府各有關部門的指導下關注基層地區的新冠醫藥保障工作。而在春節期間,公司在藥品倉增加人力,保障覆蓋全國的藥品供應鏈體系不打烊,以滿足用戶購藥需求。
阿里健康現報7.65元,升3.8%,成交4,434.61萬股,涉資3.38億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.